Well I am holding we will eventually be in an onco
Post# of 154979
(Total Views: 962)
Posted On: 03/08/2021 5:18:45 PM
Well I am holding we will eventually be in an oncology company.
Nash trial 30% filled - results early Q4.
Long haulers started March 1 50% filled already results early Q3 ¿or June/July?
HIV - receptor occupancy setback- soft maybe approval end of year.
Survival, discharge live, hospitalization very confident for extended CD12.
Nasdaq awaiting - revenue approval, equity requirement 5 million, seasoning of stock price above $4 dollars.
Mtnbc trial stop due to covid.
80 people died before day 28 8 or so after- Maboob.
Manufacture ready to support confirmation from Samsung.
If all vials are sold Nader still wants to give dividend if achieved by end of year.
Nothing concrete on gov support. Ows and other bodies reached out to after EUA approval.
Discharge alive = alive and well enough to leave hospital 28% left hospital before 28 days. .....mortality =dead
5 more patients enrolled and double blinded (?)
Absolute delta 9% and 24%
Icu cost 25000 per night!! No icu beds available 6 days earlier discharge equals more treated patients more lives saved,
Extended trial timeline - 140 patients 4 to 6 weeks. Plus 28 days
American regent ready contract issues resolved. Labeling nitya ray.
E- ind hopefully closed so trial fills quickly.
Off label no comment.
Funding “selling shares at $10” most of approved shares still available. 125 million.
Kelly vaccinated- visiting scientific board.
Samsung payment delayed (?) hopeful to pay on time (?) fuzzy.
Law, rules and regulations still proud of the team best we can do doesn’t care if it takes a year and 3 months.
Mortality over 65 - 9% reduction under 65 - 32%.
BP interest? not so much but a lot of interest in collaboration(?) on trials even offers of paying for trials only supply product.
Do treated patients develop LH? Not followed up but will be doing so as time allows.
Detailed info coming in 8k.
Solid tumor MOA s.Kelly video says it all.
Funding? For all that’s on the table? Careful ..happy with fundraising until now?!)
Trial design lack of information at time.
Dsmb forced answer not honest(?)
HIV will be in focus as well.
46 treated not included in 140
LH proof of concept looking at bio markers investigative trial. Still needs ph 3.
Mother in law dear god...not again
Basket case moving along well triple neg not open.
Janet woodcock great blowing wind up butt ....
Control in extended 140 absolutely.
Philippines takes 3 years to enroll ...shit missed one...
Selling to China ....anyone ....give us the money.
Rantes reference where is it we have lab work.
No failed trial design according to NP.
First approval difficult expansion label easier.
LA baby investor.
No more new stuff right now...
Canada IO in process timeline module more coming very soon.
Variants do not affect moa for leronlimab in covid.
Not a secretary hope it helps for people not on the call
Nash trial 30% filled - results early Q4.
Long haulers started March 1 50% filled already results early Q3 ¿or June/July?
HIV - receptor occupancy setback- soft maybe approval end of year.
Survival, discharge live, hospitalization very confident for extended CD12.
Nasdaq awaiting - revenue approval, equity requirement 5 million, seasoning of stock price above $4 dollars.
Mtnbc trial stop due to covid.
80 people died before day 28 8 or so after- Maboob.
Manufacture ready to support confirmation from Samsung.
If all vials are sold Nader still wants to give dividend if achieved by end of year.
Nothing concrete on gov support. Ows and other bodies reached out to after EUA approval.
Discharge alive = alive and well enough to leave hospital 28% left hospital before 28 days. .....mortality =dead
5 more patients enrolled and double blinded (?)
Absolute delta 9% and 24%
Icu cost 25000 per night!! No icu beds available 6 days earlier discharge equals more treated patients more lives saved,
Extended trial timeline - 140 patients 4 to 6 weeks. Plus 28 days
American regent ready contract issues resolved. Labeling nitya ray.
E- ind hopefully closed so trial fills quickly.
Off label no comment.
Funding “selling shares at $10” most of approved shares still available. 125 million.
Kelly vaccinated- visiting scientific board.
Samsung payment delayed (?) hopeful to pay on time (?) fuzzy.
Law, rules and regulations still proud of the team best we can do doesn’t care if it takes a year and 3 months.
Mortality over 65 - 9% reduction under 65 - 32%.
BP interest? not so much but a lot of interest in collaboration(?) on trials even offers of paying for trials only supply product.
Do treated patients develop LH? Not followed up but will be doing so as time allows.
Detailed info coming in 8k.
Solid tumor MOA s.Kelly video says it all.
Funding? For all that’s on the table? Careful ..happy with fundraising until now?!)
Trial design lack of information at time.
Dsmb forced answer not honest(?)
HIV will be in focus as well.
46 treated not included in 140
LH proof of concept looking at bio markers investigative trial. Still needs ph 3.
Mother in law dear god...not again
Basket case moving along well triple neg not open.
Janet woodcock great blowing wind up butt ....
Control in extended 140 absolutely.
Philippines takes 3 years to enroll ...shit missed one...
Selling to China ....anyone ....give us the money.
Rantes reference where is it we have lab work.
No failed trial design according to NP.
First approval difficult expansion label easier.
LA baby investor.
No more new stuff right now...
Canada IO in process timeline module more coming very soon.
Variants do not affect moa for leronlimab in covid.
Not a secretary hope it helps for people not on the call
(25)
(0)